<a href="https://www.medchemexpress.com/ST-193_hydrochloride.html">ST-193 (hydrochloride)</a>产品描述:ST-193 hydrochloride is a potent broad-spectrum <b>arenavirus</b> inhibitor; inhibits Guanarito, Junin, Lassa and Machupo virus with <b>IC<sub>50</sub></b> values of 0.44, 0.62, 1.4 and 3.1 nM, respectively. IC50 & Target: IC50: 0.44 nM (Guanarito), 0.62 nM (Junin), 1.4 nM (Lassa) and 3.1 nM (Machupo)<sup>[1]</sup> <i><b>In Vitro:</b></i> ST-193 inhibits LASV pseudotypes with an IC<sub>50</sub> of 1.6 nM. ST-193 inhibits pseudotypes generated with other arenavirus envelopes as well, including the remaining four commonly associated with hemorrhagic fever (IC<sub>50</sub>s for Junín, Machupo, Guanarito, and Sabiá are in the 0.2 to 12 nM range) but exhibits no antiviral activity against pseudotypes incorporating either the GP from the LASV-related arenavirus lymphocytic choriomeningitis virus or the unrelated G protein from vesicular stomatitis virus, at concentrations of up to 10 μM<sup>[2]</sup>. <i><b>In Vivo:</b></i> ST-193 is found to be tolerated well when administered daily as<br><br> <br> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">公司介绍:MedChemExpress(MCE)专注于各种抑制剂、激动剂、API及化合物库,总部位于美国新泽西,分别在瑞典和上海设有欧洲区子公司和亚洲区总代理,营销网点遍及全球20多个国家地区。MCE经过多年努力已成为全球生物活性小分子领域的一流供应商, 产品涵盖癌症、神经科学、抗感染、表观遗传学等20个热门研究领域,PI3K、MAPK等近千个细分靶点,超过4000个活性小分子化合物现货,以及GPCR、API、离子通道等超过20种不同类型的化合物库,同时提供从毫克到千克的专业定制合成服务。</span> <br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">MCE 对每批产品都进行严格的LCMS和NMR检验,其产品已被全球近万名客户广泛使用并发表大量文章、专利;</span> <br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">MCE 定期增加各领域热门抑制剂、激动剂,不断扩增已有化合物库,以满足最新的科研需求;</span> <br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">数千种产品在上海有充足备货,24-48小时内送达客户;</span> <br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">大量产品提供免费试用装;</span> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);"> 已为全球多个知名企业、院校构建各种定制型化合物库。</span><br><br>产品链接:<a href="http://www.medchemexpress.cn/st-193-hydrochloride.html">www.medchemexpress.cn/st-193-hydrochloride.html</a><br><br></span><img style="width: 600.0px;height: 310.0px;" src="http://img.dxycdn.com/trademd/upload/userfiles/image/2014/08/A1408605159png_small.jpg" alt=""> |
ST-193 (hydrochloride)研究进展
发布日期:2017-10-30 浏览次数:0
核心提示:a href=https://www.medchemexpress.com/ST-193_hydrochloride.htmlST-193 (hydrochloride)/a产品描述:ST-193 hydrochloride is
- 下一篇:暂无
- 上一篇:ST-193研究进展
行业动态
更多...
- ST-193 (hydrochloride)研 10-30
- ST-193研究进展 10-30
- Darbufelone (mesylate)研 10-30
- PGD2-IN-1研究进展 10-30
- RG13022研究进展 10-30
- NS-638研究进展 10-30
- Bamaquimast研究进展 10-30
- RG14620研究进展 10-30
- NIH-12848研究进展 10-30
- GAL-021研究进展 10-30